Introduction
============

Dyslipidemia is a common metabolic disorder that may result from abnormalities in the synthesis, processing and catabolism of lipoprotein particles. Elevated plasma total cholesterol (TC) \[[@B1]\], triglyceride (TG) \[[@B2]\], low-density lipoprotein cholesterol (LDL-C) \[[@B3]\], and apolipoprotein (Apo) B \[[@B4]\], together with decreased levels of ApoA1 \[[@B4]\] and high-density lipoprotein cholesterol (HDL-C) \[[@B5]\] are associated with an increased risk of coronary artery disease (CAD). A number of epidemiological studies have shown that in addition to environmental factors, genetic mechanisms may play a role in determining susceptibility to dyslipidemia \[[@B6]\]. The heritability estimates of the interindividual variation in plasma lipid phenotypes from both twin and family studies are in the range of 40-60% \[[@B7]\], suggesting a considerable genetic contribution, and discovery of the genes that contribute to these changes may lead to a better understanding of these processes.

ApoA1 is the predominant protein component of HDL-C, and is involved in the activation of lecithin: cholesterol acyltransferase, which mediate the reverse cholesterol transport from peripheral tissues to the liver \[[@B8]\]. ApoC3 is a major component of TG-rich lipoproteins (chylomicrons and very low density lipoprotein) and a minor component of HDL. The mature 79-amino-acid ApoC3 protein is synthesized predominantly in the liver but also to a lesser extent in the intestine. *In vitro*studies have indicated that ApoC3 is a noncompetitive inhibitor of lipoprotein lipase, thereby suggesting an important role in the catabolism of TG-rich lipoproteins \[[@B9]\]. ApoA5 is a secreted protein present in human serum and is associated with specific lipoprotein particles. It was detectable in very low-density lipoprotein, HDL, and chylomicrons. Serum ApoA5 is very low compared with other apolipoproteins \[[@B10]\]. Human ApoA1/C3/A5 gene resides in the ApoA1/C3/A4/A5 gene cluster, a short region on chromosome 11q23-q24 \[[@B11],[@B12]\]. The ApoA1/C3/A4/A5 gene cluster has been identified as a candidate region for hyperlipidemia in particular for hypertriglyceridemia and atherosclerosis \[[@B12],[@B13]\]. The association between single nucleotide polymorphisms (SNPs) in the ApoA1/C3/A4/A5 gene cluster and plasma or serum lipid levels in humans has been evaluated in a large number of studies \[[@B13]-[@B30]\]. However, previous findings on the association of the SNPs in this gene cluster with the changes in plasma lipid levels are inconsistent \[[@B31]-[@B38]\]. Many of previous studies for this gene cluster come from studies of hyperlipidemic subjects \[[@B14],[@B17],[@B18],[@B25],[@B26],[@B29],[@B33],[@B38]\] and CAD patients \[[@B13],[@B19],[@B21],[@B23],[@B34],[@B36],[@B37]\]. Studies of differences in the association between ApoA1/C3/A5 gene polymorphisms and serum lipid levels in normolipidemic men and women are extremely limited. Therefore, the aim of the present study was to detect the polymorphisms of ApoA1 -75 bp G\>A (rs1799837), ApoC3 3238C\>G (rs5128), ApoA5 -1131T\>C (rs662799), ApoA5 c.553G\>T (rs2075291) and ApoA5 c.457G\>A (rs3135507) and the association of their haplotypes and serum lipid levels in the general Chinese population.

Materials and methods
=====================

Study populations
-----------------

A total of 1030 unrelated subjects who reside in 16 villages in Napo County, Guangxi Zhuang Autonomous Region, People\'s Republic of China were randomly selected from our previous stratified randomized cluster samples \[[@B39]\]. The age of the subjects ranged from 15 to 89 years, with an average age of 43.30 ± 17.69 years. There were 492 males and 538 females. All of the subjects were rural agricultural workers. The subjects had no evidence of diseases related to atherosclerosis, CAD and diabetes. None of them had been treated with β-adrenergic blocking agents and lipid-lowering drugs such as statins or fibrates. The present study was approved by the Ethics Committee of the First Affiliated Hospital, Guangxi Medical University. Informed consent was obtained from all subjects after they received a full explanation of the study.

Epidemiological survey
----------------------

The survey was carried out using internationally standardized methods. Information on demographics, socioeconomic status, and lifestyle factors was collected with standardized questionnaires. The alcohol information included questions about the number of liangs (about 50 g) of rice wine, corn wine, rum, beer, or liquor consumed during the preceding 12 months. Alcohol consumption was categorized into groups of grams of alcohol per day: \< 25 and ≥ 25. Smoking status was categorized into groups of cigarettes per day: \< 20 and ≥ 20. At the physical examination, several parameters, such as height, weight, and waist circumference were measured. Sitting blood pressure was measured three times with the use of a mercury sphygmomanometer after the subjects had a 5-minute rest, and the average of the three measurements was used for the level of blood pressure. Systolic blood pressure was determined by the first Korotkoff sound, and diastolic blood pressure by the fifth Korotkoff sound. Body weight, to the nearest 50 grams, was measured using a portable balance scale. Subjects were weighed without shoes and in a minimum of clothing. Height was measured, to the nearest 0.5 cm, using a portable steel measuring device. From these two measurements body mass index (BMI, kg/m^2^) was calculated.

Biochemical analysis
--------------------

A venous blood sample of 8 mL was obtained from all subjects after at least 12 hours of fasting. A part of the sample (3 mL) was collected into glass tubes and used to determine serum lipid levels. Another part of the sample (5 mL) was transferred to tubes with anticoagulate solution (4.80 g/L citric acid, 14.70 g/L glucose, and 13.20 g/L tri-sodium citrate) and used to extract deoxyribonucleic acid (DNA). The levels of serum TC, TG, HDL-C, and LDL-C in samples were determined by enzymatic methods with commercially available kits (RANDOX Laboratories Ltd., Ardmore, Diamond Road, Crumlin Co. Antrim, United Kingdom, BT29 4QY; Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan). Serum ApoA1 and ApoB levels were detected by the immunoturbidimetric immunoassay using a commercial kit (RANDOX Laboratories Ltd.). All determinations were performed with an autoanalyzer (Type 7170A; Hitachi Ltd., Tokyo, Japan) in the Clinical Science Experiment Center of the First Affiliated Hospital, Guangxi Medical University \[[@B39]\].

DNA preparation and genotyping
------------------------------

Total genomic DNA was isolated from peripheral blood leukocytes using the phenol-chloroform method \[[@B8],[@B40]\]. The extracted DNA was stored at 4°C until analysis. Genotyping of the five SNPs was performed by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) \[[@B6],[@B8],[@B40]\]. The sequences of the forward and backward primers used for ApoA1 -75 bp G\>A, ApoC3 3238C\>G, and ApoA5 -1131T\>C were 5\'-CACCCGGGAGACCTGCAAGC-3\' and 5\'-TCTAAGCAGCCAGCTCTTGCA-3\', 5\'-CACTAGCCCAGAGAGAGGAGTGCC-3\' and 5\'-CTGAGCCCAGCCGCACACTAA-3\', and 5\'-GATTGATTCAAGATGCATTTAGGAC-3\' and 5\'-CCCCAGGAACTGGAGCGAAATT-3\' (Sangon, Shanghai, People\'s Republic of China); respectively. Both ApoA5 c.553G\>T and ApoA5 c.457G\>A are naturally occurring restriction enzyme sites in the exon 4 of ApoA5 gene. To analyze these two polymorphic markers, exon 4 was amplified using primers 5\'-TCGGCGTATGGGTGGAAGAG-3\' and 5\'-GGCAGCAACTGAAGCCCTACAC-3\'. Each reaction system of a total volume of 25 μL, comprised 100 ng (3 μL) of genomic DNA; 0.8 μL of each primer (20 pmo1); 4 μL of 10 × buffer solution; 3 μL dNTP; and 0.4 μL (1 U) *Taq*polymerase. For the amplification, initial denaturation at 95°C for 5 min was followed by 30 cycles of denaturation at 95°C for 15 s, annealing at 61°C for 1 min, and extension at 72°C for 1 min, with final extension at 72°C for 7 min. Each restriction enzyme reaction was performed with 15 μL of amplified DNA; 2 μL of 10 × buffer solution; and restriction ezyme (0.15 μL or 1.5 U *Msp*I for ApoA1 -75bp G\>A, 0.2 U *Sst*I for ApoC3 3238C\>G, 3 U *Tru1*I or *Mse*I for ApoA5 -1131T\>C, 4 U *Msp*I for ApoA5 c.553G\>T, and 4 U *Nsb*I or *Fsp*I for ApoA5 c.457G\>A) in a total volume of 20 μL digested at 37°C overnight. The digestive products were separated by electrophoresis on sepharose gel. The length of each digested DNA fragment was determined by comparing migration of a sample with that of standard DNA marker. Stained with ethidium bromide, the gel was visualized under ultraviolet light and photographed. Genotypes were scored by an experienced reader blinded to epidemiological data and serum lipid levels.

DNA sequencing
--------------

Twenty-eight samples (each genotype in two) detected by the PCR-RFLP were also confirmed by direct sequencing. The PCR products were purified by low melting point gel electrophoresis and phenol extraction, and then the DNA sequences were analyzed by using an ABI Prism 3100 (Applied Biosyatems) in Shanghai Sangon Biological Engineering Technology & Services Co., Ltd., People\'s Republic of China.

Diagnostic criteria
-------------------

The normal values of serum TC, TG, HDL-C, LDL-C, ApoA1, ApoB levels and the ratio of ApoA1 to ApoB in our Clinical Science Experiment Center were 3.10-5.17, 0.56-1.70, 0.91-1.81, 1.70-3.20 mmol/L, 1.00-1.76, 0.63-1.14 g/L, and 1.00-2.50; respectively \[[@B39]\]. The individuals with TC\>5.17 mmol/L and/or TG\>1.70 mmol/L were defined as hyperlipidemic \[[@B39]\]. Hypertension was diagnosed according to the criteria of 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension \[[@B41]\]. The diagnostic criteria of overweight and obesity were according to the Cooperative Meta-analysis Group of China Obesity Task Force. Normal weight, overweight and obesity were defined as a BMI \< 24, 24-28, and\>28 kg/m^2^; respectively \[[@B39]-[@B41]\].

Statistical analysis
--------------------

Epidemiological data were recorded on a pre-designed form and managed with Excel software. The statistical analyses were done with the statistical software package SPSS 13.0 (SPSS Inc., Chicago, Illinois) or SAS 9.1 (SAS Institute, Inc., Cary, North Carolina, USA). Quantitative variables were expressed as mean ± standard deviation (serum TG levels were presented as medians and interquartile ranges). Qualitative variables were expressed as percentages. Allele frequency was determined via direct counting, and the standard goodness-of-fit test was used to test the Hardy-Weinberg equilibrium. Difference in genotype distribution between the groups was obtained using the chi-square test. The difference in general characteristics between males and females was tested by the Student\'s unpaired *t*-test. The association of genotypes and serum lipid parameters was tested by analysis of covariance (ANCOVA). Age, BMI, blood pressure, alcohol consumption, and cigarette smoking were adjusted for the statistical analysis. Pair-wise linkage disequilibria (LD) among the five SNPs were estimated as correlation coefficients using the HelixTree program (GOLDEN Helix, Bozeman, MN, USA). For haplotype analysis, we estimated haplotype frequencies using the expectation-maximization algorithm, and determine the association between haplotypes and lipid phenotypes using trend regression analysis with the option of composite haplotype estimation implemented in HelixTree. *P*values were further adjusted for multiple tests by a permutation test. The permutation test was conducted by changing the orders of dependant variable randomly against the genotypes (under the null hypothesis - no association between dependant variable and haplotypes). Then haplotype trend regression was conducted based on the same model and a *P*value was recorded. This process was repeated 1000 times. The *P*values of 1000 permutations were sorted in a descending manner. If the observed *P*value is less than or equal to the 950^th^*P*value, the association was considered statistically significant. In order to evaluate the association of serum lipid levels (TC ≤ 5.17 mmol/L = 1,\>5.17 mmol/L = 2; TG ≤ 1.70 mmol/L = 1,\>1.70 mmol/L = 2; HDL-C \< 0.91 mmol/L = 1, ≥ 0.91 mmol/L = 2; LDL-C ≤ 3.20 mmol/L = 1,\>3.20 mmol/L = 2; ApoA1 \< 1.00 g/L = 1, ≥ 1.00 g/L = 2; ApoB ≤ 1.14 g/L = 1,\>1.14 g/L = 2; ApoA1/ApoB \< 1.00 = 1, ≥ 1.00 = 2) with genotypes (-75bp G\>A: GG = 1, GA = 2, AA = 3; 3238C\>G: CC = 1, CG = 2, GG = 3; -1131T\>C: TT = 1, TC = 2, CC = 3; c.553G\>T: GG = 1, GT = 2; c.457G\>A: GG = 1, GA/AA = 2) and several environment factors, unconditional logistic regression analysis with forward stepwise modeling was also performed in the combined population of males and females, males, and females; respectively. A *P*value of less than 0.05 was considered statistically significant.

Results
=======

Demographic and biochemical characteristics
-------------------------------------------

The demographic and biochemical characteristics of the participants according to sex are presented in Table [1](#T1){ref-type="table"}. The levels of body height, weight, systolic blood pressure, diastolic blood pressure, pulse pressure; the prevalence of hypertension; and the percentages of subjects who consumed alcohol or smoked cigarettes were higher in males than in females (*P*\< 0.05-0.001), whereas the levels of BMI, HDL-C and ApoA1 were lower in males than in females (*P*\< 0.05 for all). There was no significant difference in the levels of age, TC, TG, LDL-C, ApoB, and the ratio of ApoA1 to ApoB (*P*\> 0.05 for all).

###### 

Comparison of general characteristics and serum lipid levels of the participants according to sex

  -----------------------------------------------------------------------------------------
  Parameter                           Male\            Female\          *t*(χ^2^)   *P*
                                      (n = 492)        (n = 538)                    
  ----------------------------------- ---------------- ---------------- ----------- -------
  Age (years)                         43.65 ± 18.35    42.98 ± 17.07    0.607       0.544

  Height (cm)                         156.69 ± 10.25   147.88 ± 6.36    16.725      0.000

  Weight (kg)                         53.45 ± 8.99     48.17 ± 7.51     10.260      0.000

  Body mass index (kg/m^2^)           21.64 ± 2.31     21.96 ± 2.76     -2.008      0.045

   \> 24 kg/m^2^\[n (%)\]             58 (11.79)       98 (18.22)       8.260       0.004

  Systolic blood pressure (mmHg)      125.28 ± 17.14   120.55 ± 14.80   4.751       0.000

  Diastolic blood pressure (mmHg)     77.61 ± 10.46    74.45 ± 9.24     5.147       0.000

  Pulse pressure (mmHg)               47.70 ± 12.60    46.14 ± 11.35    2.090       0.037

  Hypertensive prevalence \[n (%)\]   96(19.51)        52(9.67)         20.251      0.000

  Cigarette smoking \[n (%)\]                                                       

   Nonsmoker                          200(40.6)        506(94.0)                    

   \< 20 cigarettes/day               138(28.1)        30(5.6)                      

   ≥ 20 cigarettes/day                154(31.3)        2(0.4)           348.801     0.000

  Alcohol consumption \[n (%)\]                                                     

   Nondrinker                         186(37.8)        330(61.4)                    

   \< 25 g/day                        192(39.0)        204(37.9)                    

   ≥ 25 g/day                         114(23.2)        4(0.7)           141.320     0.000

  Total cholesterol (mmol/L)          4.61 ± 1.01      4.69 ± 0.90      -1.344      0.179

  Triglycerides (mmol/L)              1.00(0.58)       0.97(0.60)       0.206       0.837

  HDL-C (mmol/L)                      2.03 ± 0.49      2.09 ± 0.46      -2.027      0.043

  LDL-C (mmol/L)                      2.36 ± 0.74      2.44 ± 0.66      -1.834      0.067

  Apolipoprotein (Apo) A1 (g/L)       1.43 ± 0.17      1.45 ± 0.13      -2.131      0.033

  ApoB (g/L)                          0.90 ± 0.22      0.92 ± 0.20      -1.528      0.127

  ApoA1/ApoB                          1.71 ± 0.58      1.66 ± 0.44      1.567       0.118
  -----------------------------------------------------------------------------------------

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. The value of triglyceride was presented as median (interquartile range). The difference between the two sexes was determined by the Wilcoxon-Mann-Whitney test.

Results of electrophoresis and genotyping
-----------------------------------------

After the genomic DNA of the samples was amplified by PCR and imaged by agarose gel electrophoresis for the ApoA1 -75 bp G\>A, the PCR product of 259 bp nucleotide sequences could be seen in the samples. The GG, GA and AA genotypes are shown in Figure [1A](#F1){ref-type="fig"}. The PCR product of the ApoC3 3238C\>G was 596 bp nucleotide sequences. The CC, CG and GG genotypes are shown in Figure [1B](#F1){ref-type="fig"}. The PCR product of the ApoA5 -1131T\>C was 188 bp nucleotide sequences. The TT, TC and CC genotypes are shown in Figure [1C](#F1){ref-type="fig"}. The PCR product of the ApoA5 c.553G\>T was 211 bp nucleotide sequences. The GG and GT genotypes are shown in Figure [1D](#F1){ref-type="fig"}. The TT genotype was not detected in our study population. The PCR product of the ApoA5 c.457G\>A was 211 bp nucleotide sequences. The GG, GA and AA genotypes are shown in Figure [1E](#F1){ref-type="fig"}.

![**Genotyping of the ApoA1/C3/A5 gene polymorphisms**. (A) ApoA1 -75 bp G\>A. Lane M, 50 bp marker ladder; lanes 1 and 2, the PCR products of the samples (259 bp); lanes 3 and 4, GA genotype (254-, 176- and 78-bp); lanes 5 and 6, GG genotype (176- and 78-bp); and lanes 7 and 8, AA genotype (254 bp). (B) ApoC3 3238C\>G. Lane M, 100 bp marker ladder; lanes 1 and 2, the PCR products of the samples (596 bp); lanes 3 and 4, CC genotype (596 bp); lanes 5 and 6, CG genotype (596-, 371- and 225-bp); and lanes 7 and 8, GG genotype (371- and 225-bp). (C) ApoA5 -1131T\>C. Lanes 1 and 2, the PCR products of the samples (188 bp); lanes 3 and 4, TT genotype (165- and 23-bp); lanes 5 and 6, TC genotype (188-, 165- and 23-bp); and Lanes 7 and 8, CC genotype (188 bp). The 23 bp fragment was invisible in the gel owing to its fast migration speed. (D) ApoA5 c.553G\>T. Lane M, 50 bp marker ladder; lanes 1 and 2, the PCR products of the samples (211 bp); lanes 3 and 4, GG genotype (176- and 35-bp); lanes 5 and 6, GT genotype (211-, 176- and 35-bp). TT genotype was not detected in both sexes. The 35 bp fragment was invisible in the gel owing to its fast migration speed. (E) ApoA5 c.457G\>A. Lanes 1 and 2, the PCR products of the samples (211 bp); lanes 3 and 4, GG genotype (211 bp); lanes 5 and 6, GA genotype (211-, 133- and 78-bp); and lanes 7 and 8, AA genotype (133- and 78-bp).](1476-511X-10-140-1){#F1}

Results of sequencing
---------------------

The results were shown as GG, GA and AA genotypes of the ApoA1 -75bp G\>A; CC, CG and GG genotypes of the ApoC3 3238C\>G; TT, TC and CC genotypes of the ApoA5 -1131T\>C; GG and GT genotypes of the ApoA5 c.553G\>T; and GG, GA and AA genotypes of the ApoA5 c.457G\>A by PCR-RFLP, the genotypes were also confirmed by sequencing (Figure [2](#F2){ref-type="fig"}); respectively. We have deposited the raw data at Genbank\'s Gene Expression Omnibus (GEO) database under accession number GRP3220754.

![**A part of the nucleotide sequences of the ApoA1/C3/A5 gene polymorphisms**. (A) ApoA1 -75 bp G\>A: (1) GG genotype, (2) GA genotype, (3) AA genotype. (B) ApoC3 3238C\>G: (1) CC genotype, (2) CG genotype, (3) GG genotype (C) ApoA5 -1131T\>C: (1) TT genotype, (2) TC genotype, (3) CC genotype; (D) ApoA5 c.553G\>T: (1) GG genotype, (2) GT genotype; (E) ApoA5 c.457G\>A: (1) GG genotype, (2) GA genotype, (3) AA genotype.](1476-511X-10-140-2){#F2}

Genotypic and allelic frequencies
---------------------------------

The genotypic frequencies of each of the five loci were all in Hardy-Weinberg equilibrium (ApoA1 -75bp G\>A: χ^2^= 3.492, *P*= 0.062; ApoC3 3238C\>G: χ^2^= 0.108, *P*= 0.743; ApoA5 -1131T\>C: χ^2^= 1.524, *P*= 0.217; ApoA5 c.553G\>T: χ^2^= 1.200, *P*= 0.273; ApoA5 c.457G\>A: χ^2^= 2.470, *P*= 0.116; respectively). For five SNPs, ApoA1 -75bp G\>A was in LD with ApoC3 3238C\>G (*P*\< 0.001), ApoA5 -1131T\>C (*P*\< 0.04), ApoA5 c.553G\>T (*P*\< 0.001), and ApoA5 c.457G\>A (*P*\< 0.002). ApoC3 3238C\>G was in LD with ApoA5 -1131T\>C (*P*\< 0.001). ApoA5 -1131T\>C was in LD with ApoA5 c.553G\>T (*P*\< 0.001) and ApoA5 c.457G\>A (*P*\< 0.001). There was no LD between ApoC3 3238C\>G and ApoA5 c.553G\>T or ApoA5 c.457G\>A; and between ApoA5 c.553G\>T and ApoA5 c.457G\>A (*P*\> 0.05 for all; Figure [3](#F3){ref-type="fig"}). The frequency of ApoC3 3238C and 3238G alleles was 70.7% and 29.3% in males, and 64.7% and 35.3% in females (*P*\< 0.01); respectively. The frequency of CC, CG and GG genotypes was 51.2%, 39.0% and 9.8% in males, and 40.2%, 49.0% and 10.8% in females (*P*\< 0.01); respectively. There was no difference in the genotypic and allelic frequencies of the ApoA1 -75bp G\>A, ApoA5 -1131T\>C, ApoA5 c.553G\>T, and ApoA5 c.457G\>A between the males and females (*P*\> 0.05 for all; Table [2](#T2){ref-type="table"}).

![**The linkage disequilibria (LD) among the five SNPs**. (A) ApoA1 -75bp G\>A, (B) ApoC3 3238C\>G, (C) ApoA5 -1131T\>C, (D) ApoA5 c.457G\>A, and (E) ApoA5 c.553G\>T. ApoA1 -75bp G\>A was in LD with ApoC3 3238C\>G (LD correlation coefficient *r*= 0.410, *P*\< 0.001), ApoA5 -1131T\>C (*r*= 0.064, *P*\< 0.04), ApoA5 c.553G\>T (*r*= 0.106, *P*\< 0.001), and ApoA5 c.457G\>A (*r*= 0.096, *P*\< 0.002). ApoC3 3238C\>G was in LD with ApoA5 -1131T\>C (*r*= 0.359, *P*\< 0.001). ApoA5 -1131T\>C was in LD with ApoA5 c.553G\>T (*r*= 0.245, *P*\< 0.001) and ApoA5 c.457G\>A (*r*= 0.165, *P*\< 0.001). There was no LD between ApoC3 3238C\>G and ApoA5 c.553G\>T (*r*= 0.059, *P*= 0.059) or ApoA5 c.457G\>A (*r*= 0.044, *P*= 0.155); and between ApoA5 c.553G\>T and ApoA5 c.457G\>A (*r*= 0.048, *P*= 0.126).](1476-511X-10-140-3){#F3}

###### 

The genotypic and allelic frequencies of ApoA1/C3/A5 gene polymorphisms between males and females

  SNP                Group    n     Genotype \[n (%)\]   Allele \[n (%)\]                           
  ------------------ -------- ----- -------------------- ------------------ ---------- ------------ -----------
  ApoA1 -75bp G\>A   Male     492   192(39.0)            242(49.2)          58(11.8)   626(63.6)    358(36.4)
  (rs1799837)        Female   538   210(39.0)            264(49.1)          64(11.9)   684(63.6)    392(36.4)
                     χ^2^     \-    0.003                0.001                                      
                     *P*      \-    0.998                0.982                                      
  ApoC3 3238C\>G     Male     492   252(51.2)            192(39.0)          48(9.8)    696(70.7)    288(29.3)
  (rs5128)           Female   538   216(40.2)            264(49.0)          58(10.8)   696(64.7)    380(35.3)
                     χ^2^     \-    13.053               8.579                                      
                     *P*      \-    0.002                0.003                                      
  ApoA5 -1131T\>C    Male     492   268(54.4)            178(36.2)          46(9.4)    714(72.6)    270(27.4)
  (rs662799)         Female   538   266(49.4)            226(42.0)          46(8.6)    758(70.4)    318(29.6)
                     χ^2^     \-    3.663                1.127                                      
                     *P*      \-    0.160                0.288                                      
  ApoA5 c.553G\>T    Male     492   466(94.7)            26(5.3)            0          958(97.4)    26(2.6)
  (rs2075291)        Female   538   496(92.2)            42(7.8)            0          1034(96.1)   42(3.9)
                     χ^2^     \-    2.651                2.561                                      
                     *P*      \-    0.103                0.109                                      
  ApoA5 c.457G\>A    Male     492   424(86.2)            64(13.0)           4(0.8)     912(92.7)    72(7.3)
  (rs3135507)        Female   538   484(90.0)            48(8.9)            6(1.1)     1016(94.4)   60(5.6)
                     χ^2^     \-    4.605                2.597                                      
                     *P*      \-    0.100                0.107                                      

Allele A: -75bp G, 3238C, -1131T, c.553G or c.457G; Allele B: -75bp A, 3238G, -1131C, c.553T or c.457A; Genotype AA: -75bp GG, 3238CC, -1131TT, c.553GG or c.457GG; Genotype AB: -75bp GA, 3238CG, -1131TC, c.553GT or c.457GA; Genotype BB: -75bp AA, 3238GG, -1131CC, c.553TT or c.457AA

Genotypes and serum lipid levels
--------------------------------

As shown in Table [3](#T3){ref-type="table"}, the levels of TG in males were different among the GG, GA and AA genotypes of the ApoA1 -75bp G\>A (*P*\< 0.003), whereas the levels of HDL-C and the ratio of ApoA1 to ApoB in females were different among the three genotypes (*P*\< 0.05 and *P*\< 0.01; respectively).

###### 

The ApoA1/C3/A5 genotypes and serum lipid levels between males and females

  ---------------------------------------------------------------------------------------------------------------------------------------
  SNP                Genotype   n     TC\           TG\          HDL-C\           LDL-C\        ApoA1\        ApoB\         ApoA1/\
                                      (mmol/L)      (mmol/L)     (mmol/L)         (mmol/L)      (g/L)         (g/L)         ApoB
  ------------------ ---------- ----- ------------- ------------ ---------------- ------------- ------------- ------------- -------------
  ApoA1 -75bp G\>A   Male                                                                                                   

  (rs1799837)        GG         192   4.57 ± 1.06   0.92(0.46)   2.02 ± 0.46      2.40 ± 0.72   1.42 ± 0.18   0.90 ± 0.22   1.67 ± 0.44

                     GA         242   4.67 ± 1.03   1.05(0.70)   2.06 ± 0.54      2.32 ± 0.79   1.45 ± 0.16   0.89 ± 0.23   1.73 ± 0.52

                     AA         58    4.51 ± 0.66   0.78(0.54)   1.94 ± 0.37      2.43 ± 0.53   1.41 ± 0.14   0.89 ± 0.21   1.77 ± 1.04

                     *F*        \-    0.867         11.673       1.458            0.894         2.408         0.117         0.914

                     *P*        \-    0.421         0.003        0.234            0.410         0.091         0.890         0.402

                     Female                                                                                                 

                     GG         210   4.73 ± 0.86   0.99(0.62)   2.15 ± 0.51      2.39 ± 0.65   1.46 ± 0.13   0.90 ± 0.21   1.74 ± 0.56

                     GA         264   4.68 ± 0.92   0.96(0.59)   2.06 ± 0.42      2.48 ± 0.66   1.45 ± 0.14   0.93 ± 0.20   1.61 ± 0.35

                     AA         64    4.61 ± 0.94   0.96(0.59)   2.01 ± 0.47      2.43 ± 0.69   1.42 ± 0.13   0.93 ± 0.21   1.60 ± 0.34

                     *F*        \-    0.477         0.236        3.273            1.094         2.153         1.369         5.689

                     *P*        \-    0.621         0.889        0.039            0.336         0.117         0.255         0.004

  ApoC3 3238C\>G     Male                                                                                                   

  (rs5128)           CC         252   4.57 ± 0.96   0.93(0.65)   1.97 ± 0.45      2.34 ± 0.76   1.42 ± 0.15   0.88 ± 0.23   1.75 ± 0.69

                     CG         192   4.61 ± 1.02   1.00(0.50)   2.11 ± 0.57^b^   2.35 ± 0.66   1.44 ± 0.19   0.89 ± 0.20   1.68 ± 0.42

                     GG         48    4.85 ± 1.21   1.02(0.60)   2.07 ± 0.36      2.57 ± 0.90   1.45 ± 0.15   0.96 ± 0.27   1.64 ± 0.46

                     *F*        \-    1.551         2.954        4.528            2.036         1.138         2.601         1.213

                     *P*        \-    0.213         0.228        0.011            0.132         0.321         0.075         0.298

                     Female                                                                                                 

                     CC         216   4.65 ± 0.80   0.92(0.60)   2.08 ± 0.42      2.45 ± 0.62   1.45 ± 0.12   0.91 ± 0.17   1.64 ± 0.31

                     CG         264   4.67 ± 0.98   0.98(0.64)   2.10 ± 0.48      2.41 ± 0.68   1.44 ± 0.14   0.92 ± 0.21   1.67 ± 0.46

                     GG         58    4.93 ± 0.87   1.02(1.00)   2.05 ± 0.53      2.56 ± 0.72   1.45 ± 0.12   0.95 ± 0.25   1.68 ± 0.73

                     *F*        \-    2.342         15.113       0.314            1.249         0.403         0.920         0.339

                     *P*        \-    0.097         0.001        0.731            0.288         0.668         0.399         0.712

  ApoA5 -1131T\>C    Male                                                                                                   

  (rs662799)         TT         268   4.56 ± 1.01   0.91(0.53)   2.04 ± 0.48      2.33 ± 0.76   1.43 ± 0.15   0.88 ± 0.22   1.76 ± 0.68

                     TC         178   4.58 ± 1.01   1.03(0.66)   1.99 ± 0.49      2.34 ± 0.70   1.42 ± 0.19   0.90 ± 0.22   1.67 ± 0.42

                     CC         46    5.08 ± 0.90   1.14(0.72)   2.15 ± 0.56      2.66 ± 0.67   1.47 ± 0.12   0.99 ± 0.22   1.57 ± 0.42

                     *F*        \-    7.637         13.443       0.535            4.492         0.135         8.091         7.797

                     *P*        \-    0.001         0.001        0.586            0.012         0.873         0.000         0.000

                     Female                                                                                                 

                     TT         266   4.60 ± 0.84   0.89(0.58)   2.09 ± 0.42      2.39 ± 0.66   1.44 ± 0.13   0.90 ± 0.19   1.69 ± 0.38

                     TC         226   4.77 ± 0.99   1.04(0.64)   2.10 ± 0.52      2.49 ± 0.67   1.45 ± 0.14   0.95 ± 0.20   1.61 ± 0.41

                     CC         46    4.79 ± 0.77   1.01(1.04)   2.03 ± 0.45      2.48 ± 0.64   1.45 ± 0.12   0.93 ± 0.25   1.74 ± 0.78

                     *F*        \-    1.662         16.015       0.272            1.233         0.333         2.154         0.278

                     *P*        \-    0.191         0.000        0.762            0.292         0.717         0.117         0.758

  ApoA5 c.553G\>T    Male                                                                                                   

  (rs2075291)        GG         466   4.61 ± 1.02   0.93(0.56)   2.05 ± 0.50      2.36 ± 0.74   1.43 ± 0.16   0.89 ± 0.22   1.72 ± 0.58

                     GT         26    4.64 ± 0.87   1.63(1.39)   1.74 ± 0.33      2.38 ± 0.75   1.39 ± 0.18   0.96 ± 0.27   1.62 ± 0.67

                     *F*        \-    0.147         4.108        3.122            0.134         1.232         1.559         0.848

                     *P*        \-    0.883         0.000        0.002            0.893         0.218         0.120         0.397

                     Female                                                                                                 

                     GG         496   4.70 ± 0.91   0.98(0.60)   2.10 ± 0.47      2.44 ± 0.66   1.45 ± 0.14   0.92 ± 0.20   1.66 ± 0.45

                     GT         42    4.60 ± 0.82   0.97(0.74)   1.97 ± 0.33      2.39 ± 0.61   1.45 ± 0.09   0.95 ± 0.21   1.60 ± 0.35

                     *F*        \-    0.689         0.844        2.359            0.474         0.000         0.930         0.843

                     *P*        \-    0.491         0.399        0.018            0.636         1.000         0.353         0.399

  ApoA5 c.457G\>A    Male                                                                                                   

  (rs3135507)        GG         424   4.63 ± 0.96   1.00(0.58)   2.07 ± 0.49      2.38 ± 0.74   1.44 ± 0.15   0.90 ± 0.22   1.72 ± 0.59

                     GA/AA      68    4.51 ± 1.26   1.01(0.63)   1.79 ± 0.43      2.30 ± 0.73   1.36 ± 0.22   0.88 ± 0.22   1.64 ± 0.50

                     *F*        \-    0.913         -0.268       4.445            0.829         3.795         0.696         1.059

                     *P*        \-    0.362         0.788        0.000            0.407         0.000         0.487         0.290

                     Female                                                                                                 

                     GG         484   4.72 ± 0.91   0.98(0.59)   2.09 ± 0.47      2.47 ± 0.66   1.45 ± 0.14   0.93 ± 0.20   1.64 ± 0.43

                     GA/AA      54    4.40 ± 0.81   0.94(0.45)   2.06 ± 0.38      2.21 ± 0.65   1.43 ± 0.10   0.84 ± 0.20   1.82 ± 0.52

                     *F*        \-    2.477         0.589        0.453            2.750         1.021         3.137         2.452

                     *P*        \-    0.014         0.556        0.651            0.006         0.309         0.002         0.014
  ---------------------------------------------------------------------------------------------------------------------------------------

SNP, single nucleotide polymorphism; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B. The values of TG were presented as median (interquartile range). The difference among the genotypes was determined by the Kruskal-Wallis test or the Wilcoxon-Mann-Whitney test.

The levels of HDL-C in males were different among the CC, CG and GG genotypes of the ApoC3 3238C\>G (*P*\< 0.05), whereas the levels of TG in females were different among the three genotypes (*P*\< 0.01).

The levels of TC, TG, LDL-C, ApoB, and the ratio of ApoA1 to ApoB in males were different among the TT, TC and CC genotypes of the ApoA5 -1131T\>C (*P*\< 0.05-0.001), whereas the levels of TG in females were different among the three genotypes (*P*\< 0.001).

The levels of TG and HDL-C in males were different between the GG and GT genotypes of the ApoA5 c.553G\>T (*P*\< 0.01 for each), whereas the levels of HDL-C in females were different between the two genotypes (*P*\< 0.05).

The levels of HDL-C and ApoA1 in males were different between the GG and GA/AA genotypes of the ApoA5 c.457G\>A (*P*\< 0.001 for each), whereas the levels of TC, LDL-C, ApoB, and the ratio of ApoA1 to ApoB in females were different between the GG and GA/AA genotypes (*P*\< 0.05-0.01).

Haplotypes and serum lipid levels
---------------------------------

To examine the combined effect of five variants (in the order of ApoA5 c.553G\>T, ApoA5 c.457G\>A, ApoA5 -1131T\>C, ApoC3 3238C\>G, ApoA1 -75bp G\>A) in the cluster, we conducted haplotype analysis with these SNPs on the serum lipid traits (Table [4](#T4){ref-type="table"}). There were 11 haplotypes with a frequency\>1% identified in the cluster in our population. To increase the statistical power of analysis, we combined five haplotypes with frequencies less than 4% into one group, called \"rare-hap\", which gives a pooled frequency of 9%. The frequencies of other six haplotypes are listed in Table [4](#T4){ref-type="table"} with G-G-T-C-G and G-G-T-C-A each accounting for 26% haplotype of the population; respectively. At the global level, the haplotypes comprised of all five SNPs were significantly associated with all seven lipid traits (Table [4](#T4){ref-type="table"}) with *P*values ranging from 1.56 × 10^-6^to 0.001 before or 0.001 to 0.003 after correcting for multiple testing by permuation test. In particular, haplotype G-G-C-C-A (6%) and G-A-T-C-G (4%) showed consistent association with TC, LDL-C, ApoA1, ApoB, and the ratio of ApoA1 to ApoB. In addition, carriers of haplotype G-G-T-C-G (26%) had increased serum concentration of HDL-C and ApoA1, whereas carriers of G-G-C-G-G (15%) had high concentrations of TC, TG, and ApoB.

###### 

Association between ApoA1/C3/A5 haplotypes and serum lipid levels in the combined population of males and females

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lipid      Haplotype                G-G-T-C-G     G-G-T-C-A     G-G-C-G-G     G-G-T-G-G     G-G-C-C-A     G-A-T-C-G     Rare Hap      Haplotype global association   
  ---------- ------------------------ ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------------------------ ------------------------
  \-         Frequency                0.26          0.26          0.15          0.13          0.06          0.04          0.09          \-                             \-

  \-         Frequency (carrier vs\   462 vs. 568   458 vs. 572   328 vs. 702   236 vs. 794   118 vs. 912   92 vs. 938    62 vs. 968    *P*                            *P*after\
             Noncarrier)                                                                                                                                               permutation correction

  TC         Carrier                  4.67 ± 0.05   4.64 ± 0.05   4.78 ± 0.06   4.71 ± 0.07   4.87 ± 0.09   4.40 ± 0.10   4.70 ± 0.08                                  

  (mmol/L)   Noncarrier               4.70 ± 0.05   4.72 ± 0.05   4.64 ± 0.05   4.68 ± 0.04   4.66 ± 0.04   4.71 ± 0.04   4.69 ± 0.04                                  

             *P*                      0.514         0.159         0.024         0.641         0.021         0.002         0.882         2.05E-04                       0.001

  TG         Carrier                  1.10 (0.07)   1.23 (0.07)   1.38 (0.08)   1.20 (0.09)   1.27 (0.12)   1.73 (0.13)   1.15 (0.16)                                  

  (mmol/L)   Noncarrier               1.33 (0.07)   1.23 (0.07)   1.16 (0.06)   1.24 (0.06)   1.23 (0.06)   1.19 (0.06)   1.24 (0.06)                                  

             *P*                      0.004         0.121         \< 0.001      0.866         0.324         0.426         0.055         1.50E-05                       0.001

  HDL-C      Carrier                  2.15 ± 0.03   2.11 ± 0.03   2.14 ± 0.03   2.14 ± 0.04   2.12 ± 0.05   1.95 ± 0.05   2.02 ± 0.04                                  

  (mmol/L)   Noncarrier               2.09 ± 0.03   2.12 ± 0.03   2.10 ± 0.02   2.11 ± 0.02   2.11 ± 0.02   2.13 ± 0.02   2.13 ± 0.02                                  

             *P*                      0.049         0.835         0.279         0.350         0.933         \< 0.001      0.014         1.56E-06                       0.001

  LDL-C      Carrier                  2.38 ± 0.04   2.37 ± 0.04   2.45 ± 0.04   2.40 ± 0.05   2.52 ± 0.06   2.14 ± 0.07   2.43 ± 0.06                                  

  (mmol/L)   Noncarrier               2.41 ± 0.04   2.42 ± 0.04   2.37 ± 0.03   2.40 ± 0.03   2.38 ± 0.03   2.42 ± 0.03   2.39 ± 0.03                                  

             *P*                      0.405         0.311         0.085         0.978         0.033         \< 0.001      0.561         0.001                          0.003

  ApoA1      Carrier                  1.48 ± 0.01   1.46 ± 0.01   1.46 ± 0.01   1.47 ± 0.01   1.49 ± 0.01   1.41 ± 0.02   1.45 ± 0.01                                  

  (g/L)      Noncarrier               1.46 ± 0.01   1.47 ± 0.01   1.47 ± 0.01   1.46 ± 0.01   1.46 ± 0.01   1.47 ± 0.01   1.47 ± 0.01                                  

             *P*                      0.025         0.581         0.832         0.272         0.043         \< 0.001      0.327         6.97E-05                       0.001

  ApoB       Carrier                  0.90 ± 0.01   0.90 ± 0.01   0.93 ± 0.01   0.91 ± 0.02   0.96 ± 0.02   0.83 ± 0.02   0.94 ± 0.02                                  

  (g/L)      Noncarrier               0.92 ± 0.01   0.92 ± 0.01   0.90 ± 0.01   0.91 ± 0.01   0.91 ± 0.01   0.92 ± 0.01   0.91 ± 0.01                                  

             *P*                      0.171         0.207         0.029         0.797         0.008         \< 0.001      0.062         6.85E-06                       0.001

  ApoA1/     Carrier                  1.72 ± 0.03   1.72 ± 0.03   1.67 ± 0.03   1.70 ± 0.04   1.59 ± 0.05   1.81 ± 0.06   1.65 ± 0.05                                  

  ApoB       Noncarrier               1.69 ± 0.03   1.69 ± 0.03   1.72 ± 0.03   1.70 ± 0.02   1.72 ± 0.02   1.69 ± 0.02   1.71 ± 0.02                                  

             *P*                      0.357         0.211         0.115         0.975         0.011         0.031         0.173         0.001                          0.003
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B

We also found that haplotypes with five SNPs explain much more serum lipid variation than any single SNP alone, especially for TG (4.4% for haplotype vs 2.4% for -1131T\>C max based on R-square) and HDL-C (5.1% for haplotype vs 0.9% for c.553G\>T based on R-square).

Correlation between genotypes and several environment factors and serum lipid levels
------------------------------------------------------------------------------------

For males, multivariate logistic regression analysis showed that the levels of TC were correlated with ApoA5 -1131T\>C genotypes; the levels of TG were correlated with ApoA1 -75bp G\>A and ApoA5 c.553G\>T genotypes, and ApoA5 c.457 G\>A, ApoA5 -1131T\>C and ApoC3 3238C\>G alleles; the levels of LDL-C were correlated with ApoC3 3238C\>G genotypes; the levels of ApoB were correlated with ApoA5 c.457 G\>A and ApoC3 3238C\>G genotypes; the ratio of ApoA1 to ApoB was correlated with ApoA1 -75bp G\>A and ApoC3 3238C\>G alleles (Table [5](#T5){ref-type="table"}).

###### 

Correlation between serum lipid parameters and alleles/genotypes in the males and females

  Lipid parameter    Risk factor                 χ^2^     *P*     Odds ratio   95% CI
  ------------------ --------------------------- -------- ------- ------------ ---------------
  Male plus female                                                             
   TC                ApoA5 -1131T\>C allele      12.284   0.000   1.704        1.265-2.295
   TG                ApoA5 c.553G\>T genotype    5.986    0.014   2.293        1.180-4.460
                     ApoA5 c.457 G\>A allele     7.713    0.005   2.243        1.268-3.968
                     ApoA5 -1131T\>C allele      6.647    0.010   1.534        1.108-2.123
                     ApoA1 -75bp G\>A genotype   5.337    0.021   0.345        0.140-0.851
   HDL-C             ApoA5 c.457 G\>A allele     7.595    0.006   16.571       2.250-12.048
   LDL-C             ApoC3 3238C\>G genotype     12.001   0.001   2.834        1.572-5.111
   ApoA1             ApoA5 c.553G\>T genotype    4.978    0.026   11.297       1.343-5.052
   ApoB              ApoC3 3238C\>G genotype     13.034   0.000   1.514        1.209-1.897
  Male                                                                         
   TC                ApoA5 -1131T\>C genotype    4.910    0.027   1.428        1.042-1.957
   TG                ApoA5 c.553G\>T genotype    17.322   0.000   7.990        3.003-21.260
                     ApoA5 c.457 G\>A allele     4.097    0.043   2.263        1.026-4.989
                     ApoA5 -1131T\>C allele      7.400    0.007   2.590        1.305-5.143
                     ApoC3 3238C\>G allele       3.904    0.048   0.503        0.254-0.995
                     ApoA1 -75bp G\>A genotype   5.372    0.020   0.240        0.072-0.802
   LDL-C             ApoC3 3238C\>G genotype     8.307    0.004   1.886        1.225-2.904
   ApoB              ApoA5 c.457 G\>A genotype   4.600    0.032   0.464        0.230-0.936
                     ApoC3 3238C\>G genotype     4.284    0.038   2.088        1.040-4.193
   ApoA1/ApoB        ApoC3 3238C\>G allele       6.836    0.009   0.354        0.163-0.771
                     ApoA1 -75bp G\>A allele     3.939    0.047   6.065        1.023-35.968
  Female                                                                       
   TC                ApoA5 -1131T\>C allele      19.701   0.000   2.651        1.724-4.078
   TG                ApoC3 3238C\>G genotype     26.171   0.000   3.149        2.029-4.887
   ApoB              ApoA5 c.457 G\>A allele     7.720    0.005   2.961        1.377-6.368
                     ApoA5 -1131T\>C genotype    5.390    0.020   1.600        1.076-2.379
                     ApoC3 3238C\>G allele       14.382   0.000   3.403        1.807-6.407
                     ApoA1 -75bp G\>A genotype   6.842    0.009   3.043        1.322-7.007
                     ApoA1 -75bp G\>A allele     4.409    0.036   0.318        0.109-0.927
   ApoA1/ApoB        ApoA5 -1131T\>C genotype    7.771    0.005   6.339        1.730-23.221
                     ApoC3 3238C\>G allele       5.542    0.019   13.522       1.546-118.228
                     ApoA1 -75bp G\>A genotype   5.519    0.019   14.950       1.566-142.771
                     ApoA1 -75bp G\>A allele     7.989    0.005   0.017        0.001-0.287

TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B

For females, the levels of TC were correlated with ApoA5 -1131T\>C alleles; the levels of TG were correlated with ApoC3 3238C\>G genotypes, the levels of ApoB were correlated with ApoA1 -75bp G\>A and ApoA5 -1131T\>C genotypes, ApoA1 -75bp G\>A, ApoC3 3238C\>G and ApoA5 c.457 G\>A alleles; the ratio of ApoA1 to ApoB was correlated with ApoA1 -75bp G\>A and ApoA5 -1131T\>C genotypes, and ApoA1 -75bp G\>A and ApoC3 3238C\>G alleles (Table [5](#T5){ref-type="table"}).

Serum lipid parameters were also correlated with several environment factors such as age, alcohol consumption, cigarette smoking, blood pressure, body weight, and BMI (Table [6](#T6){ref-type="table"}).

###### 

Correlation between serum lipid parameters and several environmental factors in the males and females

  Lipid parameter    Risk factor                χ^2^     *P*     Odds ratio   95% CI
  ------------------ -------------------------- -------- ------- ------------ --------------
  Male plus female                                                            
   TC                Age                        53.062   0.000   1.034        1.025-1.043
                     Height                     8.532    0.003   0.847        0.757-0.947
                     Weight                     10.525   0.001   1.329        1.119-1.578
                     Body mass index            6.797    0.009   0.593        0.401-0.878
                     Cigarette smoking          6.455    0.011   0.748        0.598-0.936
   TG                Age                        6.792    0.009   1.017        1.004-1.029
                     Height                     16.601   0.000   0.777        0.688-0.877
                     Weight                     16.820   0.000   1.476        1.225-1.778
                     Body mass index            9.241    0.002   0.522        0.343-0.794
                     Alcohol consumption        10.147   0.001   1.606        1.200-2.149
   LDL-C             Ethnic group               10.381   0.001   0.492        0.320-0.758
                     Sex                        5.359    0.021   1.728        1.088-2.747
                     Age                        28.500   0.000   1.038        1.024-1.052
                     Weight                     44.497   0.000   1.099        1.069-1.129
                     Alcohol consumption        4.813    0.028   0.702        0.511-0.963
   ApoA1             Height                     13.117   0.000   1.451        1.186-1.775
                     Weight                     9.403    0.002   0.719        0.583-0.888
                     Diastolic blood pressure   7.697    0.006   0.892        0.822-0.967
                     Cigarette smoking          6.813    0.009   7.213        1.636-13.806
   ApoB              Sex                        4.652    0.031   0.665        0.459-0.963
                     Height                     4.215    0.040   0.903        0.819-0.995
                     Weight                     5.765    0.016   1.213        1.036-1.419
                     Body mass index            4.364    0.037   0.678        0.471-0.976
                     Alcohol consumption        5.787    0.016   0.744        0.585-0.947
   ApoA1/ApoB        Ethnic group               3.987    0.046   1.752        1.010-3.037
                     Height                     9.623    0.002   0.815        0.716-0.927
                     Weight                     12.059   0.001   1.451        1.176-1.791
                     Body mass index            14.889   0.000   0.374        0.227-0.616
  Male                                                                        
   TC                Age                        5.116    0.024   1.016        1.002-1.031
                     Height                     5.474    0.019   0.956        0.921-0.993
                     Weight                     26.172   0.000   1.113        1.068-1.160
   TG                Weight                     20.023   0.000   1.152        1.083-1.226
                     Diastolic blood pressure   4.879    0.027   0.967        0.938-0.996
                     Alcohol consumption        14.437   0.000   2.291        1.494-3.513
   LDL-C             Ethnic group               5.224    0.022   0.449        0.226-0.892
                     Age                        8.301    0.004   1.035        1.011-1.060
                     Height                     14.963   0.000   1.096        1.046-1.148
                     Body mass index            22.094   0.000   1.418        1.226-1.640
   ApoA1             Height                     6.700    0.010   18.279       2.025-5.008
                     Weight                     6.201    0.013   0.022        0.001-0.442
   ApoB              Height                     4.635    0.031   0.866        0.760-0.987
                     Weight                     5.439    0.020   1.285        1.041-1.587
                     Body mass index            4.398    0.036   0.576        0.345-0.965
                     Systolic blood pressure    9.347    0.002   1.026        1.009-1.044
                     Alcohol consumption        4.211    0.040   0.736        0.549-0.986
   ApoA1/ApoB        Ethnic group               4.973    0.026   2.286        1.105-4.731
  Female                                                                      
   TC                Age                        46.796   0.000   1.051        1.036-1.066
                     Weight                     6.720    0.010   1.040        1.010-1.071
   TG                Age                        8.060    0.005   1.028        1.009-1.048
                     Height                     14.564   0.000   0.648        0.519-0.810
                     Weight                     13.307   0.000   1.956        1.364-2.805
                     Body mass index            9.570    0.002   0.288        0.131-0.643
                     Systolic blood pressure    5.469    0.019   1.024        1.004-1.045
   HDL-C             Systolic blood pressure    3.389    0.048   0.870        0.758-0.999
   LDL-C             Ethnic group               5.274    0.022   0.506        0.283-0.905
                     Age                        14.902   0.000   1.038        1.018-1.058
                     Height                     5.072    0.024   1.061        1.008-1.116
                     Body mass index            11.305   0.001   1.175        1.070-1.291
   ApoA1             Weight                     4.470    0.034   0.258        0.074-0.906
                     Systolic blood pressure    6.152    0.013   0.583        0.380-0.893
                     Pulse pressure             5.363    0.021   1.526        1.067-2.183
   ApoB              Age                        14.358   0.000   1.032        1.015-1.049
                     Weight                     5.156    0.023   1.460        1.053-2.023
                     Body mass index            4.428    0.035   0.462        0.225-0.948
                     Pulse pressure             4.620    0.032   0.975        0.952-0.998
                     Cigarette smoking          4.129    0.042   0.303        0.096-0.959
   ApoA1/ApoB        Age                        6.236    0.013   1.037        1.008-1.067
                     Height                     9.500    0.002   0.547        0.373-0.803
                     Weight                     9.508    0.002   2.833        1.461-5.492
                     Body mass index            11.423   0.001   0.080        0.019-0.346
                     Pulse pressure             5.817    0.016   0.942        0.897-0.989

TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B

Discussion
==========

The results of the present study clearly show that the levels of serum HDL-C and ApoA1 in the general Chinese population were higher in females than in males. There was no significant difference in the levels of TC, TG, LDL-C, ApoB and the ratio of ApoA1 to ApoB between the two sexes. These findings are in good agreement with those of previous epidemiological studies \[[@B42],[@B43]\]. Although the effects of gonadal hormones on blood lipids are considered contributing factors, the reasons for sex differences in serum lipid levels are still not fully understood. It is commonly accepted that androgens induce changes in lipid concentrations that would predispose towards CAD, whereas estrogens are held to have opposite effects \[[@B44],[@B45]\]. However, much of the evidence for this comes from studies of changes associated with administration of synthetic gonadal steroids or with changes in gonadal function. Studies of differences in lipid metabolism in normal men and women are extremely limited.

There exists significant racial variation of allelic frequencies in this gene cluster, but the present study shows that there was no significant difference in the allelic and genotypic frequencies of the all SNPs except ApoC3 3238C\>G between males and females. The frequency of ApoC3 3238G allele was lower in males than in females (29.3% vs. 35.3%, *P*\< 0.01). The frequency of CG and GG genotypes was also lower in males than in females (*P*\< 0.01). The frequency of ApoA1 -75bp A allele was higher in our population than in Liangshan Yi (23.0%), the other minority in China \[[@B46]\], and Caucasians (12.4-21.8%) in the western countries \[[@B47],[@B48]\]. Rare allelic frequency of Caucasians from different nations was similar and significantly lower than that of oriental races. The frequency of ApoC3 3238G allele in our population was consistent with ranges reported for Chinese (30-43%) \[[@B29],[@B49]\], Japanese (25-48%) \[[@B50]\] and Indians (36%) \[[@B51]\], but are higher than that reported for Caucasians in whom the G allele frequency was 0-11% \[[@B51],[@B52]\]. The ApoA5 -1131C allele in our study population was similar to that in Chinese (29.9%) \[[@B53],[@B54]\], Singaporean Chinese (29.4%) \[[@B55]\], Malays (30.0%) \[[@B55]\], slightly lower than that in Japanese (34.0%) \[[@B56],[@B57]\], but much greater than that of whites (8.0%) \[[@B12]\], Hispanic Americans (16.0%) \[[@B16],[@B58],[@B59]\] or Tunisian (13.0%) \[[@B60]\]. The frequency of ApoA5 c.553T allele in this study is extremely low, and is in agreement with that of two previous studies in Chinese (3.97%) \[[@B61]\] and Chinese Taiwanese (4.2-7.2%) \[[@B62],[@B63]\]. The ApoA5 c.553T allele has been reported to be absent in Caucasians \[[@B64]\]. The ApoA5 c.553TT homozygous was not detected in our study population. This is similar to the results in a previous study \[[@B61]\]. The frequency of ApoA5 c.457A allele was lower in our study population than in Chinese Taiwanese (10.27%) \[[@B54]\], but was higher than that reported for Czechoslovakians in whom the ApoA5 c.457A allele frequency was 2.04% \[[@B65]\]. These results suggest that there exists significant racial/ethinc variation of allelic frequencies in the ApoA1/C3/A5 gene cluster.

The association of the ApoA1/C3/A5 gene polymorphisms and plasma or serum lipid levels in humans has been evaluated in a large number of studies \[[@B13]-[@B30]\]. However, previous findings are inconsistent \[[@B31]-[@B38]\]. Talmud et al. \[[@B66]\] found that the ApoA1 -75 bp A allele induced elevated HDL-C and ApoA1 levels. This relationship was also demonstrated in many other studies, but with sex-dependent: Jeenah et al. \[[@B67]\] and Sigurdsson et al. \[[@B68]\] found in British and Icelandic male respectively that A allele confered high serum ApoA1 levels. Xu et al. \[[@B69]\] reported A allele carriers had higher mean levels of TC, LDL-C, ApoB and ApoA1 than G homozygotes in Italian boys. Nevertheless, Pagani et al. \[[@B70]\] discovered A allele was positively related to HDL-C concentration in Italian female exclusively. There were also some studies detecting no correlation between the ApoA1 -75 bp G\>A and serum lipids pattern \[[@B31],[@B32]\]. Previous cohort studies, as well as case-control and familial studies have shown significant association between the ApoC3 3238G allele and higher plasma TG levels \[[@B13]-[@B30]\]. However, several reports failed to find a significant genetic effect on TG concentrations \[[@B33]-[@B35]\]. In a previous work, Kee and coworkers found no association between ApoC3 3238C\>G polymorphism and lipids, lipoproteins and complex lipoprotein particles in a sample of men from northern France \[[@B34]\]. They thought that the ApoC3 3238C\>G polymorphism is not major contributors to the risk of dyslipidemia in the population of northern France. Several separate clinical studies have provided consistent and strong support for the effect with 24% of whites, 35% of blacks, and 53% of Hispanics who carry ApoA5 -1131C allele associated with increased plasma TG levels \[[@B12],[@B16],[@B58]\]. But this association was not significant in a population-based Spanish control group \[[@B38]\]. The ApoA5 c.553G\>T polymorphism has been found to correlate strongly with TG levels in Chinese but not in Caucasians \[[@B62],[@B64]\]. The ApoA5 c.553T allele carriers had significantly higher plasma TG levels compared to the wide-type GG genotype, in both CAD and control groups. In a previous study, however, Tang et al. \[[@B61]\] did not find any significant associations between the ApoA5 c.553G\>T polymorphism and plasma lipid parameters such as TC, LDL-C, HDL-C, ApoA1, and ApoB in Han Chinese recruited from Jiangsu Province, People\'s Republic of China. The association of the ApoA5 c.457G\>A polymorphism and plasma lipid levels in humans has not been fully elucidated. In a previous study, Kao et al. \[[@B62]\] showed that the ApoA5 c.457G\>A polymorphism was not associated with serum TG levels in normal people. In another recent study, Hubacek et al. \[[@B65]\] showed that the impact of statin treatment on lipid parameters did not significantly differ between carriers of the genotypes defined by the ApoA5 c.457G\>A polymorphisms. In the present study, we showed that the ApoA5 c.457A allele carriers in males had lower serum HDL-C and ApoA1 levels than the A allele noncarriers, whereas the ApoA5 c.457A allele carriers in females had lower serum TC, LDL-C and ApoB levels and higher the ratio of ApoA1 to ApoB than the A allele noncarriers.

Important intra- and inter-genic LD associations have been found in this study, which replicate previous findings \[[@B26]-[@B30]\]. These LD patterns in ApoA1/C3/A5 are rather complex and highly specific to the population under study and indicate the functional dependencies of the encoded proteins \[[@B24]\]. In the present study, haplotype analysis with all five SNPs further supports the strong association between ApoA1/C3/A5 gene polymorphisms and serum lipid levels in our study population. At the global level, the haplotypes comprised of all five SNPs were significantly associated with all seven lipid traits after correcting for multiple testing by permuation test. In particular, haplotype G-G-C-C-A and G-A-T-C-G showed consistent association with LDL-C, TC, ApoA1, ApoB, and the ratio of ApoA1 to ApoB. In addition, carriers of haplotype G-G-T-C-G had increased serum concentration of HDL-C and ApoA1, whereas carriers of G-G-C-G-G had high concentrations of TG, TC, and ApoB. We also found that haplotypes with five SNPs explain much more serum lipid variation than any single SNP alone, especially for TG and HDL-C.

The present study has some shortcomings. Firstly, the size of our study population is a bit small, which might not have had the power to detect the LD across the ApoA1/C3/A5 locus. The individual with ApoA5 c.553TT genotype is not detected in our population, and the number of subjects with ApoA5 c.457AA genotype in both sexes is also small. It has been postulated that an adequate analysis of the polymorphic variants of the ApoA1/ApoC3/ApoA4 gene complex requires a sample of at least 600 subjects to allow the detection of a twofold increased risk of disease \[[@B71]\]. Secondly, the levels of body height, weight, systolic blood pressure, diastolic blood pressure, pulse pressure, the prevalence of hypertension, and the percentages of subjects who consumed alcohol or smoked cigarettes were higher in males than in femailes. Although age, BMI, blood pressure, alcohol consumption, and cigarette smoking have been adjusted for the statistical analysis, we can not completely exclude the influence of these factors on serum lipid levels among different genotypes in both sexes. Thirdly, because we selected the SNPs from literature and did not cover the extensive ApoA1/C3/A4/A5 gene locus, we might miss some information from other SNPs. We did not include ApoA4 SNPs in this study, because there is no ApoA4 SNP is associated with hypertriglyceridemia \[[@B29]\], except ApoA4 T347S associated with a TG-lowering effect \[[@B16]\]. Chien et al. \[[@B30]\] have analyzed amino acid 360 (G to T substitution, Glu to His) and amino acid 347 (A to T, Thr to Ser) of the ApoA4 gene but the results showed no substitution was found in a community-based population.

Conclusion
==========

The present study shows that the allelic and genotypic frequencies of the all SNPs except ApoC3 3238C\>G were not different between males and females, but all five SNPs at the ApoA1/C3/A5 gene cluster and their haplotypes are closely associated with modifications of serum lipid parameters in both sexes. The haplotypes with five SNPs explain much more serum lipid variation than any single SNP alone, especially for TG and HDL-C in the general Chinese population.
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